# E. Shelley Hwang

Source: https://onco.cc/people/shelley-hwang/  
OnCo record `shelley-hwang` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Duke surgeon who led COMET, the trial testing whether women with low-risk DCIS can safely be monitored instead of having surgery straight away.

## Summary

Shelley Hwang is a breast surgeon at Duke Cancer Institute whose research asks whether ductal carcinoma in situ is overtreated. She led the COMET trial, which randomised women with low-risk DCIS to guideline-concordant care or active monitoring with endocrine therapy, and was first author of its 2024 JAMA report showing that the rate of invasive cancer at two years was not worse with monitoring. She also leads laboratory work on the biology of DCIS progression.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: breast; surgery; de-escalation; trialist
- Role: Breast surgical oncologist, Duke Cancer Institute
- Specialisms: Ductal carcinoma in situ; Active monitoring; Surgical de-escalation

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Ductal carcinoma in situ (DCIS)](https://onco.cc/cancers/ductal-carcinoma-in-situ/)
- institutions: [Duke Cancer Institute](https://onco.cc/institutions/duke-cancer-institute/)
- trials: [COMET (Comparison of Operative versus Monitoring and Endocrine Therapy)](https://onco.cc/trials/comet-dcis/)

---
JSON: https://onco.cc/api/v1/entities/shelley-hwang.json